Coming soon

Events

See what BetaGlue will attend
San Francisco - JP Morgan Health Conference

44th Annual J.P. Morgan

Healthcare Conference

January 12-15, 2026 | San Francisco, California

Register interest: info@betaglue.com


Alexis
Peyroles
CEO
Salvatore
Calabrese
CFO
Gianluca
De Danieli
Head of Clinical Development
Spectrum Miami

Advancements in the fight against cancer

Spectrum Conference

January 15-17, 2026 | Miami (FL), USA

Register interest: info@betaglue.com


Alexis
Peyroles
CEO
Salvatore
Calabrese
CFO
Gianluca
De Danieli
Head of Clinical Development
MioLive - Roma

World Congress of Interventional Oncology

MIOLive

January 26-27, 2026 | Rome

Register interest: info@betaglue.com


Gianluca
De Danieli
Head of Clinical Development

What we’re building

News

Discover the latest from our lab and clinic
ENEA-Tech Biomedical Foundation Invests €6m in BetaGlue® Therapeutics Bringing 2024 Funding Round Total to €24m
ENEA TECH - BIO MEDICAL

ENEA-Tech Biomedical Foundation Invests €6m in BetaGlue® Therapeutics Bringing 2024 Funding Round Total to €24m

Milan, December 16th 2024 - BetaGlue® Therapeutics S.p.A. (“BetaGlue”) an Italian clinical-stage oncology company developing an innovative radiotherapy platform for the targeted and personalised treatment of unresectable solid tumours, called…

Read more
1201 801 Betaglue® Therapeutics
BetaGlue® Adds €8m Equity Financing to €10m EIC Accelerator Award
Colin Story - BetaGlue

BetaGlue® Adds €8m Equity Financing to €10m EIC Accelerator Award

Milan, June 6, 2024 – BetaGlue® Therapeutics (“BetaGlue” or the “Company”) a clinical-stage radiotherapy company developing novel products for the personalised treatment of solid tumour cancers today announces the closing…

Read more
1201 801 Betaglue® Therapeutics
BetaGlue® Therapeutics Announces the Appointment of Mike Cogswell as Chairman and Mike Maszy as Non-Executive Director
New Betaglue board members

BetaGlue® Therapeutics Announces the Appointment of Mike Cogswell as Chairman and Mike Maszy as Non-Executive Director

Milan, May 15, 2024 – BetaGlue® Therapeutics (“BetaGlue” or the “Company”) a clinical-stage company developing novel radiotherapy products for the personalised treatment of solid tumour cancers today announces the appointment…

Read more
1200 800 Betaglue® Therapeutics